+关注
ZN节节高
暂无个人介绍
IP属地：山西
311
关注
0
粉丝
3
主题
0
勋章
主贴
热门
ZN节节高
2021-09-09
👍👍👍
抱歉，原内容已删除
ZN节节高
2021-08-24
👍
抱歉，原内容已删除
ZN节节高
2021-08-23
👍
抱歉，原内容已删除
ZN节节高
2021-08-19
😀
抱歉，原内容已删除
ZN节节高
2021-08-10
💰
港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元
ZN节节高
2021-07-30
👍
抱歉，原内容已删除
ZN节节高
2021-06-14
很看好😁
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3585559413011129","uuid":"3585559413011129","gmtCreate":1622531349287,"gmtModify":1622531349287,"name":"ZN节节高","pinyin":"znjjgznjiejiegao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":311,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":3,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.49%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.92%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"山西","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":889563403,"gmtCreate":1631159088402,"gmtModify":1631159088402,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585559413011129","authorIdStr":"3585559413011129"},"themes":[],"title":"","htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889563403","repostId":"2166318109","repostType":2,"isVote":1,"tweetType":1,"viewCount":4109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834942494,"gmtCreate":1629768953718,"gmtModify":1629768953718,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585559413011129","authorIdStr":"3585559413011129"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/834942494","repostId":"1197906344","repostType":2,"isVote":1,"tweetType":1,"viewCount":3011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832520994,"gmtCreate":1629671024718,"gmtModify":1629671024718,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585559413011129","authorIdStr":"3585559413011129"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/832520994","repostId":"2161747789","repostType":2,"isVote":1,"tweetType":1,"viewCount":2654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831747249,"gmtCreate":1629354102581,"gmtModify":1629354102581,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585559413011129","authorIdStr":"3585559413011129"},"themes":[],"title":"","htmlText":"😀","listText":"😀","text":"😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831747249","repostId":"2160517887","repostType":2,"isVote":1,"tweetType":1,"viewCount":3954,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896832755,"gmtCreate":1628567285177,"gmtModify":1628567285177,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585559413011129","authorIdStr":"3585559413011129"},"themes":[],"title":"","htmlText":"💰","listText":"💰","text":"💰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896832755","repostId":"2158429616","repostType":2,"repost":{"id":"2158429616","kind":"news","pubTimestamp":1628559311,"share":"https://www.laohunote.com/m/news/2158429616?lang=zh_CN&edition=full","pubTime":"2021-08-10 09:35","market":"hk","language":"zh","title":"港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2158429616","media":"智通财经","summary":"智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成846位受试者的入组工作。三期研究的设计旨在确定BRII-196/BRII-198联合疗法能否在研究的28天中预防住院或死亡的复合终点。若后续数据积极，将有可能被授予EUA(紧急使用权)。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/02137\">腾盛博药-B</a>(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。</p><p>消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成846位受试者的入组工作。三期研究的设计旨在确定BRII-196/BRII-198联合疗法能否在研究的28天中预防住院或死亡的复合终点。若后续数据积极，将有可能被授予EUA(紧急使用权)。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 09:35 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/530668.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/530668.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8484c32aa045a32d4ca87a47aef4e825","relate_stocks":{"02137":"腾盛博药-B"},"source_url":"http://www.zhitongcaijing.com/content/detail/530668.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158429616","content_text":"智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成846位受试者的入组工作。三期研究的设计旨在确定BRII-196/BRII-198联合疗法能否在研究的28天中预防住院或死亡的复合终点。若后续数据积极，将有可能被授予EUA(紧急使用权)。","news_type":1,"symbols_score_info":{"02137":1}},"isVote":1,"tweetType":1,"viewCount":3303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808474790,"gmtCreate":1627608476910,"gmtModify":1627608476910,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585559413011129","authorIdStr":"3585559413011129"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808474790","repostId":"1109337387","repostType":2,"isVote":1,"tweetType":1,"viewCount":2620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184976452,"gmtCreate":1623682587976,"gmtModify":1623682587976,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585559413011129","authorIdStr":"3585559413011129"},"themes":[],"title":"","htmlText":"很看好😁","listText":"很看好😁","text":"很看好😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184976452","isVote":1,"tweetType":1,"viewCount":4167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":832520994,"gmtCreate":1629671024718,"gmtModify":1629671024718,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585559413011129","idStr":"3585559413011129"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/832520994","repostId":"2161747789","repostType":2,"isVote":1,"tweetType":1,"viewCount":2654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834942494,"gmtCreate":1629768953718,"gmtModify":1629768953718,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585559413011129","idStr":"3585559413011129"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/834942494","repostId":"1197906344","repostType":2,"isVote":1,"tweetType":1,"viewCount":3011,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808474790,"gmtCreate":1627608476910,"gmtModify":1627608476910,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585559413011129","idStr":"3585559413011129"},"themes":[],"title":"","htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808474790","repostId":"1109337387","repostType":2,"isVote":1,"tweetType":1,"viewCount":2620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889563403,"gmtCreate":1631159088402,"gmtModify":1631159088402,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585559413011129","idStr":"3585559413011129"},"themes":[],"title":"","htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/889563403","repostId":"2166318109","repostType":2,"repost":{"id":"2166318109","kind":"news","pubTimestamp":1631075548,"share":"https://www.laohunote.com/m/news/2166318109?lang=zh_CN&edition=full","pubTime":"2021-09-08 12:32","market":"us","language":"zh","title":"理想汽车官微宣布：理想ONEOTA2.2即将推送，更聪明的“理想同学”，全...","url":"https://stock-news.laohu8.com/highlight/detail?id=2166318109","media":"新浪财经","summary":"理想汽车官微宣布：理想ONEOTA2.2即将推送，更聪明的“理想同学”，全新应用商店同步上线。","content":"<html><body><a href=\"https://laohu8.com/S/LI\">理想汽车</a>官微宣布：理想ONEOTA2.2即将推送，更聪明的“理想同学”，全新应用商店同步上线。</body></html>","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>理想汽车官微宣布：理想ONEOTA2.2即将推送，更聪明的“理想同学”，全...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n理想汽车官微宣布：理想ONEOTA2.2即将推送，更聪明的“理想同学”，全...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-08 12:32 北京时间 <a href=https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2021-09-08/doc-iktzscyx2984808.shtml><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>理想汽车官微宣布：理想ONEOTA2.2即将推送，更聪明的“理想同学”，全新应用商店同步上线。</p>\n\n<a href=\"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2021-09-08/doc-iktzscyx2984808.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c3461c9400040bdfdce3ecdd4882fbed","relate_stocks":{"02015":"理想汽车-W","LI":"理想汽车"},"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2021-09-08/doc-iktzscyx2984808.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166318109","content_text":"理想汽车官微宣布：理想ONEOTA2.2即将推送，更聪明的“理想同学”，全新应用商店同步上线。","news_type":1,"symbols_score_info":{"LI":1,"02015":1}},"isVote":1,"tweetType":1,"viewCount":4109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831747249,"gmtCreate":1629354102581,"gmtModify":1629354102581,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585559413011129","idStr":"3585559413011129"},"themes":[],"title":"","htmlText":"😀","listText":"😀","text":"😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831747249","repostId":"2160517887","repostType":2,"repost":{"id":"2160517887","kind":"news","pubTimestamp":1629342240,"share":"https://www.laohunote.com/m/news/2160517887?lang=zh_CN&edition=full","pubTime":"2021-08-19 11:04","market":"us","language":"zh","title":"蔚来“自动驾驶”事件引起争议，李想、周鸿祎、沈晖接连发声","url":"https://stock-news.laohu8.com/highlight/detail?id=2160517887","media":"界面新闻","summary":"蔚来“自动驾驶”事件引起争议，李想、周鸿祎、沈晖接连发声8月12日，美一好创始人林文钦驾驶蔚来ES8启用自动驾驶功能后，发生交通事故，不幸逝世。不仅使蔚来处于舆论漩涡，也引发外界对辅助驾驶与自动驾驶的讨论。对此，蔚来方面人士回应称，NOP领航辅助并不是自动驾驶，后续有结果，将会向外界同步信息。尽管该事件引发外界对自动驾驶的质疑，甚至业内出现取消自动驾驶的声音，但他坚信自动驾驶的前景光明。","content":"<div>\n<p>原标题：蔚来“自动驾驶”事件引起争议，李想、周鸿祎、沈晖接连发声8月12日，美一好创始人林文钦驾驶蔚来ES8启用自动驾驶功能后，发生交通事故，不幸逝世。不仅使蔚来处于舆论漩涡，也引发外界对辅助驾驶与自动驾驶的讨论。美一好发出的讣告显示，林文钦在驾驶蔚来ES8汽车启用自动驾驶功能（NOP领航状态）后，在沈海高速涵江段发生交通事故后逝世。言下之意是，美一好方面认为，此次事故与蔚来自动驾驶功能（NOP...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202108191123127d507eb6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>蔚来“自动驾驶”事件引起争议，李想、周鸿祎、沈晖接连发声</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n蔚来“自动驾驶”事件引起争议，李想、周鸿祎、沈晖接连发声\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 11:04 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202108191123127d507eb6&s=b><strong>界面新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>原标题：蔚来“自动驾驶”事件引起争议，李想、周鸿祎、沈晖接连发声8月12日，美一好创始人林文钦驾驶蔚来ES8启用自动驾驶功能后，发生交通事故，不幸逝世。不仅使蔚来处于舆论漩涡，也引发外界对辅助驾驶与自动驾驶的讨论。美一好发出的讣告显示，林文钦在驾驶蔚来ES8汽车启用自动驾驶功能（NOP领航状态）后，在沈海高速涵江段发生交通事故后逝世。言下之意是，美一好方面认为，此次事故与蔚来自动驾驶功能（NOP...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202108191123127d507eb6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/1e9aa56586a03fdd6464e21bfe99f7b5","relate_stocks":{"03601":"鲁大师","02015":"理想汽车-W","NIO":"蔚来","LI":"理想汽车"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202108191123127d507eb6&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2160517887","content_text":"原标题：蔚来“自动驾驶”事件引起争议，李想、周鸿祎、沈晖接连发声8月12日，美一好创始人林文钦驾驶蔚来ES8启用自动驾驶功能后，发生交通事故，不幸逝世。不仅使蔚来处于舆论漩涡，也引发外界对辅助驾驶与自动驾驶的讨论。美一好发出的讣告显示，林文钦在驾驶蔚来ES8汽车启用自动驾驶功能（NOP领航状态）后，在沈海高速涵江段发生交通事故后逝世。言下之意是，美一好方面认为，此次事故与蔚来自动驾驶功能（NOP领航状态）有关。林文钦好友林伟伟也表示，“林文钦认为自动驾驶是电动车和油车的区别，自动驾驶是他买这辆车的核心。”林伟伟透露，林文钦在购买蔚来前多次向蔚来销售人员询问自动驾驶，但蔚来销售人员均未正面回答，而是分享最近销售记录，并炫耀“中午定了好多台”。对此，蔚来方面人士回应称，NOP领航辅助并不是自动驾驶，后续有结果，将会向外界同步信息。我也注意到，蔚来方面曾多次声明，NOP领航辅助不等于自动驾驶。比如，去年蔚来自动辅助驾驶负责人章健勇在《领航辅助（NOP）使用指南》一文中写道，“大家绝对不能把NOP等同于自动驾驶。NOP仍然是一种辅助驾驶功能，且随时可能在无法满足工作条件的情况下退出。”说白了，NOP领航辅助并不等于自动驾驶，尚未没有达到自动驾驶应该具备的功能，只能作为一种辅助功能使用，离自动驾驶还很远。但怪就怪在，蔚来在宣传时，使用户容易产生这就是自动驾驶的错觉，似乎有误导用户的嫌疑。换言之，目前自动驾驶还不成熟，用户对于如何使用智能驾驶、受到哪些限制，往往不能正确、全面理解，汽车厂商在大肆宣传不成熟的自动驾驶功能时，无形中让用户对汽车功能产生误解。而一旦产生误解，代价可能就是宝贵的生命，决定汽车厂商必须慎之又慎，不能只顾商业利益，而对用户生命缺乏足够的敬畏。事实上，目前市场上销售的量产车型中，最高级别仅能做到L2。当然，有部分车企在宣传上有意打擦边球，将自身驾驶辅助功能定义为L2.5甚至L2.9，但至今没有任何一家车企公开宣布量产车已达到L3级别。一个重要的原因在于，由L2到L3是自动驾驶技术研发道路上风险最大的一次跃升，目前车企在技术上无法做到100%保险。因此，在自动驾驶尚未完全成熟的情况下，过度依赖自动驾驶是有风险的，用户应对自动驾驶潜在风险保持清醒的认识，并具备主动学习和安全相关的交通意识。同时，针对自动驾驶，汽车厂商要理性宣传，而不是过度宣传，提前且充分告知用户相关风险，避免让用户陷入认知误区。鉴于蔚来是造车新势力头部玩家，发生伤亡事故后，顿时引发行业热议。理想汽车掌门人李想在朋友圈发文，呼吁媒体和行业机构统一自动驾驶的中文名词标准，避免夸张地宣传造成用户使用的误解。“L2、L3什么的用户听不懂，建议统一名称：L2=辅助驾驶；L3=自动辅助驾驶；L4=自动驾驶；L5=无人驾驶。一个多余的中文字也不要有，避免夸张地宣传造成用户使用的误解。在推广上克制，在技术上投入，对用户、行业、企业都长期有利。”李想说道。他的建议得到哪吒汽车投资人、360掌门人周鸿祎的高度认可，“人工智能不是营销话术，没有那么神奇，自动驾驶无人驾驶还有很多路要走很多坑要填，不能为了营销误导用户。L2到L5都是行业黑话自娱自乐，应该变成普通用户可以望文生义的简单概念。”威马汽车掌门人沈晖则表示，L2级别辅助驾驶功能，驾驶员是功能操作主体，也是责任主体；L4以上级别自动驾驶功能，车内无人状态下，操作主体是车辆本身，责任主体当归属主机厂。尽管该事件引发外界对自动驾驶的质疑，甚至业内出现取消自动驾驶的声音，但他坚信自动驾驶的前景光明。沈晖表示，在通往自动驾驶的路上，或许会因为种种黑天鹅时刻而暂缓，但再多荆棘都只会是插曲，对于方向的探索和技术的研发永远不会停止，也不应该停止。就像蒸汽汽车会战胜四轮马拉的驿车一样，历史的车轮永远向前。他直言，没人在现阶段有能力做到全场景自动驾驶，包括威马。技术瓶颈就像暗疾，更早暴露是件好事，在技术方案不成熟之前可以趁早找到替代预案，没什么能够凌驾生命之上。“在尊重生命的根本原则之上，我们需要那些激进的技术先锋者，去创新、去实践、去变革。”我认同沈晖的观点，自动驾驶大势所趋，不会因为一两起事故就中断甚至停止，伤亡事故的发生固然不幸，但会促使汽车厂商审视、反思自身的技术缺陷，从而不断优化、迭代、完善技术，带来更安全、更便捷的驾驶体验。当自动驾驶越来越安全，本身就是尊重生命的体现，只不过这条路注定道阻且长。换言之，发生悲剧后，别对自动驾驶因噎废食，请不要失去对新技术的信心与善意，多给予一些“发芽开花”的时间，让自动驾驶来证明自己。做个小调查：你是否看好自动驾驶的未来？责任编辑：王翔","news_type":1,"symbols_score_info":{"LI":1,"02015":1,"03601":1,"NIO":1}},"isVote":1,"tweetType":1,"viewCount":3954,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896832755,"gmtCreate":1628567285177,"gmtModify":1628567285177,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585559413011129","idStr":"3585559413011129"},"themes":[],"title":"","htmlText":"💰","listText":"💰","text":"💰","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/896832755","repostId":"2158429616","repostType":2,"repost":{"id":"2158429616","kind":"news","pubTimestamp":1628559311,"share":"https://www.laohunote.com/m/news/2158429616?lang=zh_CN&edition=full","pubTime":"2021-08-10 09:35","market":"hk","language":"zh","title":"港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2158429616","media":"智通财经","summary":"智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成846位受试者的入组工作。三期研究的设计旨在确定BRII-196/BRII-198联合疗法能否在研究的28天中预防住院或死亡的复合终点。若后续数据积极，将有可能被授予EUA(紧急使用权)。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/02137\">腾盛博药-B</a>(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。</p><p>消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成846位受试者的入组工作。三期研究的设计旨在确定BRII-196/BRII-198联合疗法能否在研究的28天中预防住院或死亡的复合终点。若后续数据积极，将有可能被授予EUA(紧急使用权)。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 腾盛博药-B(02137)再涨超10%破顶 近三日累涨近80% 总市值已突破300亿港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-10 09:35 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/530668.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/530668.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/8484c32aa045a32d4ca87a47aef4e825","relate_stocks":{"02137":"腾盛博药-B"},"source_url":"http://www.zhitongcaijing.com/content/detail/530668.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158429616","content_text":"智通财经APP获悉，腾盛博药-B(02137)连续三日暴涨，累计涨幅近80%。该股早盘继续获资金追捧，盘中涨超10%，高见44.35港元，继续刷新上市新高。截至发稿，涨8%，报43.2港元，成交额4535.3万港元，总市值已突破300亿港元。消息面上，公司宣布其BRII-196/BRII-198自研产品新冠中和抗体产品的ACTIV-2三期临床研究已在美国、巴西、南非、墨西哥及阿根廷的研究中心完成846位受试者的入组工作。三期研究的设计旨在确定BRII-196/BRII-198联合疗法能否在研究的28天中预防住院或死亡的复合终点。若后续数据积极，将有可能被授予EUA(紧急使用权)。","news_type":1,"symbols_score_info":{"02137":1}},"isVote":1,"tweetType":1,"viewCount":3303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184976452,"gmtCreate":1623682587976,"gmtModify":1623682587976,"author":{"id":"3585559413011129","authorId":"3585559413011129","name":"ZN节节高","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585559413011129","idStr":"3585559413011129"},"themes":[],"title":"","htmlText":"很看好😁","listText":"很看好😁","text":"很看好😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/184976452","isVote":1,"tweetType":1,"viewCount":4167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
